Non-Small Cell Lung Cancer

  • Tarceva 2016 report

    Tarceva 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 21 Pages The 5 Key Questions Addressed by this Report:...

  • Tecentriq 2016 report

    Tecentriq 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 24 Pages The 5 Key Questions Addressed by this Report:...

  • Xalkori 2016 report

    Xalkori 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 21 Pages The 5 Key Questions Addressed by this Report:...

  • Zykadia 2016 report

    Zykadia 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 24 Pages The 5 Key Questions Addressed by this Report:...

  • Abraxane 2015 report

    Abraxane 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 27 Pages The 5 Key Questions Addressed by this...

  • Alimta 2015 report

    Alimta 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 25 Pages The 5 Key Questions Addressed by this...

  • Avastin 2015 report

    Avastin 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 26 Pages The 5 Key Questions Addressed by this...

  • Cyramza 2015 report

    Cyramza 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 25 Pages The 5 Key Questions Addressed by this...

  • Gilotrif 2015 report

    Gilotrif 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 27 Pages The 5 Key Questions Addressed by this...

  • Iressa 2015 report

    Iressa 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 25 Pages The 5 Key Questions Addressed by this...

  • Keytruda 2015 report

    Keytruda 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 25 Pages The 5 Key Questions Addressed by this...

  • Opdivo 2015 report

    Opdivo 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 28 Pages The 5 Key Questions Addressed by this...